AstraZeneca's drug Wainua failed a key trial, causing its shares to fall 9%, the largest drop in the FTSE 100 that day. Jefferies notes the impact on the stock price exceeds the drug's actual valuation contribution, which is about 2% of net present value. The failure raises concerns about management's trial design, especially due to a high increase in patients on a competing drug during the study. Despite this, patients on Wainua alone showed a significant 29% reduction in events. The setback does not threaten AstraZeneca's long-term $80 billion sales target for 2030, but investor confidence may remain low until upcoming trial results in lung cancer are released.
ResearchAndMarkets.com released a comprehensive report covering over 1,350 precision medicine collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, financial terms, and partnership strategies, ...
Royalty Pharma reported a 6% increase in Portfolio Receipts to $773 million in Q2 2026, driven by a 14% rise in Royalty Receipts from key drugs like Tremfya and Evrysdi. The company acquired new royalty interests, including AstraZeneca’s cliramitug, ...
Pomerantz LLP is investigating AstraZeneca and some of its executives for potential securities fraud following the failure of the Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy. The trial did not meet its primary e...
SOPHiA GENETICS announced a multi-year collaboration with AstraZeneca to develop and commercialize two companion diagnostics supporting precision oncology therapies. The partnership will focus on creating decentralized diagnostics for solid tumors an...
